Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2026
Changes in Abdominal Adiposity and Associations With Metabolic Health Markers Following Tirzepatide in Japanese Participants With Obesity Disease: Results From the SURMOUNT-J Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Waki Hironori, Kaneyuki Eiji, Shingaki Tomotaka, Oura Tomonori, Nagakubo Takashi, Ishigaki Yasushi
Аннотация
OBJECTIVES: This analysis characterized obesity-related outcomes in SURMOUNT-J and explored relationships among weight loss, abdominal adiposity, and metabolic improvements.
METHODS: Japanese adults with obesity disease without diabetes were randomized (1:1:1) to tirzepatide (10 or 15 mg) or placebo plus lifestyle modification. Prespecified analyses evaluated changes from baseline to week 72 in obesity and glycemic parameters. Post hoc analyses assessed correlations among changes in weight, anthropometrics, abdominal adiposity (visceral adipose tissue [VAT], subcutaneous adipose tissue [SAT], hepatic fat fraction [HFF]), and glycemic outcomes.
RESULTS: Among 225 participants (placebo n=75; tirzepatide 10 mg n=73; 15 mg n=77), tirzepatide significantly increased high molecular weight adiponectin (mean change: 78.9% and 88.4% vs 0.9%) and reduced leptin (-57.3% and -63.1% vs -8.4%), high-sensitivity C-reactive protein (-55.1% and -65.3% vs -17.7%), and liver-related markers, including procollagen III (-21.3% and -24.8% vs -3.8%) and cytokeratin-18 (-59.8% and -62.0% vs -32.8%) (all P<.001). Glucose, insulin, and C-peptide AUC during a 75-g oral glucose tolerance test were also significantly reduced. At week 72, weight loss correlated linearly with reductions in adiposity. Weight loss was strongly correlated with VAT reduction (r=0.722-0.837 across groups), and VAT reductions strongly correlated with waist measures (r=0.837). Weight and VAT reductions showed moderate correlations with reductions in glucose, insulin, and C-peptide AUC (r=0.378-0.656).
CONCLUSION: Tirzepatide-induced reductions in body weight and VAT were associated with improvements in metabolic markers and glucose metabolism. Strong associations between anthropometric measures and VAT support their use as surrogate markers of visceral adiposity in Japanese patients with obesity disease.
METHODS: Japanese adults with obesity disease without diabetes were randomized (1:1:1) to tirzepatide (10 or 15 mg) or placebo plus lifestyle modification. Prespecified analyses evaluated changes from baseline to week 72 in obesity and glycemic parameters. Post hoc analyses assessed correlations among changes in weight, anthropometrics, abdominal adiposity (visceral adipose tissue [VAT], subcutaneous adipose tissue [SAT], hepatic fat fraction [HFF]), and glycemic outcomes.
RESULTS: Among 225 participants (placebo n=75; tirzepatide 10 mg n=73; 15 mg n=77), tirzepatide significantly increased high molecular weight adiponectin (mean change: 78.9% and 88.4% vs 0.9%) and reduced leptin (-57.3% and -63.1% vs -8.4%), high-sensitivity C-reactive protein (-55.1% and -65.3% vs -17.7%), and liver-related markers, including procollagen III (-21.3% and -24.8% vs -3.8%) and cytokeratin-18 (-59.8% and -62.0% vs -32.8%) (all P<.001). Glucose, insulin, and C-peptide AUC during a 75-g oral glucose tolerance test were also significantly reduced. At week 72, weight loss correlated linearly with reductions in adiposity. Weight loss was strongly correlated with VAT reduction (r=0.722-0.837 across groups), and VAT reductions strongly correlated with waist measures (r=0.837). Weight and VAT reductions showed moderate correlations with reductions in glucose, insulin, and C-peptide AUC (r=0.378-0.656).
CONCLUSION: Tirzepatide-induced reductions in body weight and VAT were associated with improvements in metabolic markers and glucose metabolism. Strong associations between anthropometric measures and VAT support their use as surrogate markers of visceral adiposity in Japanese patients with obesity disease.